Stefan Schwarz1, Alan P Johnson2. 1. Institute of Farm Animal Genetics, Friedrich-Loeffler-Institut (FLI), Neustadt-Mariensee, Germany stefan.schwarz@fli.bund.de. 2. Department of Healthcare-Associated Infection and Antimicrobial Resistance, National Infection Service, Public Health England, London NW9 5EQ, UK.
Abstract
In this Leading article, we summarize current knowledge of the occurrence of the first and so far only transferable colistin resistance gene, mcr-1 Its location on a conjugative plasmid is likely to have driven its spread into a range of enteric bacteria in humans and animals. Screening studies have identified mcr-1 in five of the seven continents and retrospective studies in China have identified this gene in Escherichia coli originally isolated in the 1980s, while the first European isolate dates back to 2005. Based on the widespread use of colistin in pigs and poultry in several countries and the higher number of mcr-1-carrying isolates of animal origin than of human origin, it is tempting to assume that this resistance may have emerged in the animal sector. Whatever its origin, interventions to reduce its further spread will require an integrated global one-health approach, comprising robust antibiotic stewardship to reduce unnecessary colistin use, improved infection prevention, and control and surveillance of colistin usage and resistance in both veterinary and human medicine.
In this Leading article, we summarize current knowledge of the occurrence of the first and so far only transferable colistin resistance gene, mcr-1 Its location on a conjugative plasmid is likely to have driven its spread into a range of enteric bacteria in humans and animals. Screening studies have identified mcr-1 in five of the seven continents and retrospective studies in China have identified this gene in Escherichia coli originally isolated in the 1980s, while the first European isolate dates back to 2005. Based on the widespread use of colistin in pigs and poultry in several countries and the higher number of mcr-1-carrying isolates of animal origin than of human origin, it is tempting to assume that this resistance may have emerged in the animal sector. Whatever its origin, interventions to reduce its further spread will require an integrated global one-health approach, comprising robust antibiotic stewardship to reduce unnecessary colistin use, improved infection prevention, and control and surveillance of colistin usage and resistance in both veterinary and human medicine.
Authors: Daniel Farias Monte; Andressa Mem; Miriam R Fernandes; Louise Cerdeira; Fernanda Esposito; Julia A Galvão; Bernadette D G M Franco; Nilton Lincopan; Mariza Landgraf Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Richard J Meinersmann; Scott R Ladely; Jodie R Plumblee; Kimberly L Cook; Eileen Thacker Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191
Authors: Sally R Partridge; Vincenzo Di Pilato; Yohei Doi; Michael Feldgarden; Daniel H Haft; William Klimke; Samir Kumar-Singh; Jian-Hua Liu; Surbhi Malhotra-Kumar; Arjun Prasad; Gian Maria Rossolini; Stefan Schwarz; Jianzhong Shen; Timothy Walsh; Yang Wang; Basil Britto Xavier Journal: J Antimicrob Chemother Date: 2018-10-01 Impact factor: 5.790